The EGF receptor family as targets for cancer therapy - PubMed (original) (raw)
Review
. 2000 Dec 27;19(56):6550-65.
doi: 10.1038/sj.onc.1204082.
Affiliations
- PMID: 11426640
- DOI: 10.1038/sj.onc.1204082
Review
The EGF receptor family as targets for cancer therapy
J Mendelsohn et al. Oncogene. 2000.
Abstract
Human carcinomas frequently express high levels of receptors in the EGF receptor family, and overexpression of at least two of these receptors, the EGF receptor (EGFr) and closely related ErbB2, has been associated with a more aggressive clinical behavior. Further, transfection or activation of high levels of these two receptors in nonmalignant cell lines can lead to a transformed phenotype. For these reasons therapies directed at preventing the function of these receptors have the potential to be useful anti-cancer treatments. In the last two decades monoclonal antibodies (MAbs) which block activation of the EGFr and ErbB2 have been developed. These MAbs have shown promising preclinical activity and 'chimeric' and 'humanized' MAbs have been produced in order to obviate the problem of host immune reactions. Clinical activity with these antibodies has been documented: trastuzumab, a humanized anti-ErbB2 MAb, is active and was recently approved in combination with paclitaxel for the therapy of patients with metastatic ErbB2-overexpressing breast cancer; IMC-C225, a chimeric anti-EGFr MAb, has shown impressive activity when combined with radiation therapy and reverses resistance to chemotherapy. In addition to antibodies, compounds that directly inhibit receptor tyrosine kinases have shown preclinical activity and early clinical activity has been reported. A series of phase III studies with these antibodies and direct tyrosine kinase inhibitors are ongoing or planned, and will further address the role of these active anti-receptor agents in the treatment of patients with cancer.
Similar articles
- The ErbB receptors as targets for breast cancer therapy.
Albanell J, Baselga J. Albanell J, et al. J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):337-51. doi: 10.1023/a:1018762216147. J Mammary Gland Biol Neoplasia. 1999. PMID: 10705918 Review. - AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. Traxler P, et al. Cancer Res. 2004 Jul 15;64(14):4931-41. doi: 10.1158/0008-5472.CAN-03-3681. Cancer Res. 2004. PMID: 15256466 - Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Ciardiello F, et al. Clin Cancer Res. 1999 Apr;5(4):909-16. Clin Cancer Res. 1999. PMID: 10213228 - A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello F, Tortora G. Ciardiello F, et al. Clin Cancer Res. 2001 Oct;7(10):2958-70. Clin Cancer Res. 2001. PMID: 11595683 Review.
Cited by
- Revealing the Potency of Growth Factors in Bovine Colostrum.
Yalçıntaş YM, Duman H, López JMM, Portocarrero ACM, Lombardo M, Khallouki F, Koch W, Bordiga M, El-Seedi H, Raposo A, Alves JLB, Karav S. Yalçıntaş YM, et al. Nutrients. 2024 Jul 21;16(14):2359. doi: 10.3390/nu16142359. Nutrients. 2024. PMID: 39064802 Free PMC article. Review. - HER2 Overexpression in Periampullary Tumors According to Anatomical and Histological Classification-A Systematic Review.
Bodea IC, Ciocan A, Zaharie FV, Bodea R, Graur F, Ursu Ș, Ciocan RA, Al Hajjar N. Bodea IC, et al. J Pers Med. 2024 Apr 27;14(5):463. doi: 10.3390/jpm14050463. J Pers Med. 2024. PMID: 38793045 Free PMC article. Review. - Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis.
Morau MV, Seguin CS, Visacri MB, Pincinato EC, Moriel P. Morau MV, et al. Genes (Basel). 2024 May 7;15(5):591. doi: 10.3390/genes15050591. Genes (Basel). 2024. PMID: 38790220 Free PMC article. Review. - RIZ2 at the crossroad of the EGF/EGFR signaling in colorectal cancer.
Di Donato M, Di Zazzo E, Salvati A, Sorrentino C, Giurato G, Fiore D, Proto MC, Rienzo M, Casamassimi A, Gazzerro P, Bifulco M, Castoria G, Weisz A, Nassa G, Abbondanza C. Di Donato M, et al. J Transl Med. 2023 Oct 18;21(1):736. doi: 10.1186/s12967-023-04621-6. J Transl Med. 2023. PMID: 37853459 Free PMC article. - Himalayan flora: targeting various molecular pathways in lung cancer.
James A, Akash K, Sharma A, Bhattacharyya S, Sriamornsak P, Nagraik R, Kumar D. James A, et al. Med Oncol. 2023 Oct 3;40(11):314. doi: 10.1007/s12032-023-02171-x. Med Oncol. 2023. PMID: 37787816 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous